Subscribe Us

header ads

Recents

header ads

Heparin Market Size, Growth, Demands Outlook and Forecasts to 2030

Precedence Research - February 03, 2023

According to the research report, the global heparin market size is expected to touch USD 14.6 Billion by 2030, from USD 10.53 Billion in 2022, growing with a significant CAGR of 4.17% from 2022 to 2030. 


Heparin Market Size 2021 to 2030

The heparin report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global heparin in conjunction with the geographical landscape of this vertical have also been included in this report.

The report offers intricate dynamics about different aspects of the global heparin market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global heparin during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).

Sample Link @ https://www.precedenceresearch.com/sample/1754

 Report Scope of the Heparin Market

Report CoverageDetails
Market Size by 2030USD 14.6 Billion
Growth Rate from 2022 to 2030

CAGR of 4.17%

Largest MarketNorth America 
Fastest Growing Market Asia-Pacific
Base Year2021
Forecast Period2022 to 2030
Segments CoveredType, Route of Administration, Packaging, Container, Therapeutics, Treatment, Availability, Application, Source, Ingredients, Strength, End Use, Distribution Channel, Geography

This study covers a detailed segmentation of the global heparin market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global heparin market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.

Key Players

  • GlaxoSmithKline plc
  • Pfizer, Inc.
  • Baxter
  • Leo Pharma A/S
  • Sanofi
  • Dr. Reddy’s Laboratories Ltd.
  • Aspen Holdings
  • B. Braun Medical Inc.
  • Fresenius SE & Co. KGaA
  • Teva Pharmaceutical Industries Ltd.

Market Segmentation

 By Type

  • Low Molecular Weight Heparin
  • Ultra-low Molecular Weight Heparin
  • Unfractionated Heparin

By Route of Administration

  • Intravenous
  • Subcutaneous

By Packaging

  • Glass
  • Plastic

By Container

  • Bottles
  • Bags
  • Vials
  • Others

By Therapeutics

  • Cardiovascular
  • Respiratory
  • Oncology
  • Nephrology
  • CNS
  • Others

By Treatment

  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Arterial Thromboembolism
  • Others

By Availability

  • Raw
  • Processed

By Application

  • Venous Thromboembolism
  • Atrial Fibrillation
  • Renal Impairment
  • Coronary Artery Disease
  • Others

By Source

  • Bovine
  • Porcine

By Ingredients

  • Sodium
  • Calcium
  • Others

By Strength

  • 10 Unit
  • 100 Unit
  • 1000 Unit
  • 5000 Unit
  • 10000 Unit
  • 25000 Unit
  • Others

By End Use

  • Hospitals
  • Clinics
  • Homecare
  • Ambulatory Surgical Centres
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy and Drug Store
  • Online Pharmacy
  • Others

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa

Research Methodology

The research methodology adopted by analysts for compiling the global heparin report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global heparin market.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Heparin Market, By Type

7.1. Heparin Market, by Type, 2022-2030

7.1.1. Low Molecular Weight Heparin

7.1.1.1. Market Revenue and Forecast (2017-2030)

7.1.2. Ultra-low Molecular Weight Heparin

7.1.2.1. Market Revenue and Forecast (2017-2030)

7.1.3. Unfractionated Heparin

7.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 8. Global Heparin Market, By Route of Administration

8.1. Heparin Market, by Route of Administration, 2022-2030

8.1.1. Intravenous

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Subcutaneous

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Heparin Market, By Packaging

9.1. Heparin Market, by Packaging, 2022-2030

9.1.1. Glass

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Plastic

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Heparin Market, By Container

10.1. Heparin Market, by Container, 2022-2030

10.1.1. Bottles

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Bags

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Vials

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Heparin Market, By Therapeutics

11.1. Heparin Market, by Therapeutics, 2022-2030

11.1.1. Cardiovascular

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Respiratory

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Oncology

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Nephrology

11.1.4.1. Market Revenue and Forecast (2017-2030)

11.1.5. CNS

11.1.5.1. Market Revenue and Forecast (2017-2030)

11.1.6. Others

11.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Heparin Market, By Treatment

12.1. Heparin Market, by Treatment, 2022-2030

12.1.1. Deep Vein Thrombosis

12.1.1.1. Market Revenue and Forecast (2017-2030)

12.1.2. Pulmonary Embolism

12.1.2.1. Market Revenue and Forecast (2017-2030)

12.1.3. Arterial Thromboembolism

12.1.3.1. Market Revenue and Forecast (2017-2030)

12.1.4. Others

12.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Heparin Market, By Availability

13.1. Heparin Market, by Availability, 2022-2030

13.1.1. Raw

13.1.1.1. Market Revenue and Forecast (2017-2030)

13.1.2. Processed

13.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 14. Global Heparin Market, By Application

14.1. Heparin Market, by Application, 2022-2030

14.1.1. Venous Thromboembolism

14.1.1.1. Market Revenue and Forecast (2017-2030)

14.1.2. Atrial Fibrillation

14.1.2.1. Market Revenue and Forecast (2017-2030)

14.1.3. Renal Impairment

14.1.3.1. Market Revenue and Forecast (2017-2030)

14.1.4. Coronary Artery Disease

14.1.4.1. Market Revenue and Forecast (2017-2030)

14.1.5. Others

14.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 15. Global Heparin Market, By Source

15.1. Heparin Market, by Source, 2022-2030

15.1.1. Bovine

15.1.1.1. Market Revenue and Forecast (2017-2030)

15.1.2. Porcine

15.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 16. Global Heparin Market, By Ingredients

16.1. Heparin Market, by Ingredients, 2022-2030

16.1.1. Sodium

16.1.1.1. Market Revenue and Forecast (2017-2030)

16.1.2. Calcium

16.1.2.1. Market Revenue and Forecast (2017-2030)

16.1.3. Others

16.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 17. Global Heparin Market, By Strength

17.1. Heparin Market, by Strength, 2022-2030

17.1.1. 10 Unit

17.1.1.1. Market Revenue and Forecast (2017-2030)

17.1.2. 100 Unit

17.1.2.1. Market Revenue and Forecast (2017-2030)

17.1.3. 1000 Unit

17.1.3.1. Market Revenue and Forecast (2017-2030)

17.1.4. 5000 Unit

17.1.4.1. Market Revenue and Forecast (2017-2030)

17.1.5. 10000 Unit

17.1.5.1. Market Revenue and Forecast (2017-2030)

17.1.6. 25000 Unit

17.1.6.1. Market Revenue and Forecast (2017-2030)

17.1.7. Others

17.1.7.1. Market Revenue and Forecast (2017-2030)

Chapter 18. Global Heparin Market, By End Use

18.1. Heparin Market, by End Use, 2022-2030

18.1.1. Hospitals

18.1.1.1. Market Revenue and Forecast (2017-2030)

18.1.2. Clinics

18.1.2.1. Market Revenue and Forecast (2017-2030)

18.1.3. Homecare

18.1.3.1. Market Revenue and Forecast (2017-2030)

18.1.4. Ambulatory Surgical Centres

18.1.4.1. Market Revenue and Forecast (2017-2030)

18.1.5. Others

18.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 19. Global Heparin Market, By Distribution Channel

19.1. Heparin Market, by Distribution Channel, 2022-2030

19.1.1. Hospital Pharmacy

19.1.1.1. Market Revenue and Forecast (2017-2030)

19.1.2. Retail Pharmacy and Drug Store

19.1.2.1. Market Revenue and Forecast (2017-2030)

19.1.3. Online Pharmacy

19.1.3.1. Market Revenue and Forecast (2017-2030)

19.1.4. Others

19.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 20. Global Heparin Market, Regional Estimates and Trend Forecast

20.1. North America

20.1.1. Market Revenue and Forecast, by Type (2017-2030)

20.1.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

20.1.3. Market Revenue and Forecast, by Packaging (2017-2030)

20.1.4. Market Revenue and Forecast, by Container (2017-2030)

20.1.5. Market Revenue and Forecast, by Therapeutics (2017-2030)

20.1.6. Market Revenue and Forecast, by Availability (2017-2030)

20.1.7. Market Revenue and Forecast, by Treatment (2017-2030)

20.1.8. Market Revenue and Forecast, by Application (2017-2030)

20.1.9. Market Revenue and Forecast, by Source (2017-2030)

20.1.10. Market Revenue and Forecast, by Ingredients (2017-2030)

20.1.11. Market Revenue and Forecast, by Strength (2017-2030)

20.1.12. Market Revenue and Forecast, by End Use (2017-2030)

20.1.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)

20.1.12. U.S.

20.1.12.1. Market Revenue and Forecast, by Type (2017-2030)

20.1.12.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

20.1.12.3. Market Revenue and Forecast, by Packaging (2017-2030)

20.1.12.4. Market Revenue and Forecast, by Container (2017-2030)

20.1.12.5. Market Revenue and Forecast, by Therapeutics (2017-2030)

20.1.12.6. Market Revenue and Forecast, by Availability (2017-2030)

20.1.12.7. Market Revenue and Forecast, by Treatment (2017-2030)

20.1.12.8. Market Revenue and Forecast, by Application (2017-2030)

20.1.12.9. Market Revenue and Forecast, by Source (2017-2030)

20.1.12.10. Market Revenue and Forecast, by Ingredients (2017-2030)

20.1.12.11. Market Revenue and Forecast, by Strength (2017-2030)

20.1.12.12. Market Revenue and Forecast, by End Use (2017-2030)

20.1.12.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)

20.1.13. Rest of North America

20.1.13.1. Market Revenue and Forecast, by Type (2017-2030)

20.1.13.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

20.1.13.3. Market Revenue and Forecast, by Packaging (2017-2030)

20.1.13.4. Market Revenue and Forecast, by Container (2017-2030)

20.1.13.5. Market Revenue and Forecast, by Therapeutics (2017-2030)

20.1.13.6. Market Revenue and Forecast, by Availability (2017-2030)

20.1.13.7. Market Revenue and Forecast, by Treatment (2017-2030)

20.1.13.8. Market Revenue and Forecast, by Application (2017-2030)

20.1.13.9. Market Revenue and Forecast, by Source (2017-2030)

20.1.13.10. Market Revenue and Forecast, by Ingredients (2017-2030)

20.1.13.11. Market Revenue and Forecast, by Strength (2017-2030)

20.1.12.12. Market Revenue and Forecast, by End Use (2017-2030)

20.1.13.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)

20.2. Europe

20.2.1. Market Revenue and Forecast, by Type (2017-2030)

20.2.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

20.2.3. Market Revenue and Forecast, by Packaging (2017-2030)

20.2.4. Market Revenue and Forecast, by Container (2017-2030)

20.2.5. Market Revenue and Forecast, by Therapeutics (2017-2030)

20.2.6. Market Revenue and Forecast, by Availability (2017-2030)

20.2.7. Market Revenue and Forecast, by Treatment (2017-2030)

20.2.8. Market Revenue and Forecast, by Application (2017-2030)

20.2.9. Market Revenue and Forecast, by Source (2017-2030)

20.2.10. Market Revenue and Forecast, by Ingredients (2017-2030)

20.2.11. Market Revenue and Forecast, by Strength (2017-2030)

20.2.12. Market Revenue and Forecast, by End Use (2017-2030)

20.2.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)

20.2.12. UK

20.2.12.1. Market Revenue and Forecast, by Type (2017-2030)

20.2.12.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

20.2.12.3. Market Revenue and Forecast, by Packaging (2017-2030)

20.2.12.4. Market Revenue and Forecast, by Container (2017-2030)

20.2.12.5. Market Revenue and Forecast, by Therapeutics (2017-2030)

20.2.12.6. Market Revenue and Forecast, by Availability (2017-2030)

20.2.12.7. Market Revenue and Forecast, by Treatment (2017-2030)

20.2.12.8. Market Revenue and Forecast, by Application (2017-2030)

20.2.12.9. Market Revenue and Forecast, by Source (2017-2030)

20.2.12.10. Market Revenue and Forecast, by Ingredients (2017-2030)

20.2.12.11. Market Revenue and Forecast, by Strength (2017-2030)

20.2.12.12. Market Revenue and Forecast, by End Use (2017-2030)

20.2.12.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)

20.2.13. Germany

20.2.13.1. Market Revenue and Forecast, by Type (2017-2030)

20.2.13.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

20.2.13.3. Market Revenue and Forecast, by Packaging (2017-2030)

20.2.13.4. Market Revenue and Forecast, by Container (2017-2030)

20.2.13.5. Market Revenue and Forecast, by Therapeutics (2017-2030)

20.2.13.6. Market Revenue and Forecast, by Availability (2017-2030)

20.2.13.7. Market Revenue and Forecast, by Treatment (2017-2030)

20.2.13.8. Market Revenue and Forecast, by Application (2017-2030)

20.2.13.9. Market Revenue and Forecast, by Source (2017-2030)

20.2.13.10. Market Revenue and Forecast, by Ingredients (2017-2030)

20.2.13.11. Market Revenue and Forecast, by Strength (2017-2030)

20.2.13.12. Market Revenue and Forecast, by End Use (2017-2030)

20.2.13.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)

20.2.14. France

20.2.14.1. Market Revenue and Forecast, by Type (2017-2030)

20.2.14.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

20.2.14.3. Market Revenue and Forecast, by Packaging (2017-2030)

20.2.14.4. Market Revenue and Forecast, by Container (2017-2030)

20.2.14.5. Market Revenue and Forecast, by Therapeutics (2017-2030)

20.2.14.6. Market Revenue and Forecast, by Availability (2017-2030)

20.2.14.7. Market Revenue and Forecast, by Treatment (2017-2030)

20.2.14.8. Market Revenue and Forecast, by Application (2017-2030)

20.2.14.9. Market Revenue and Forecast, by Source (2017-2030)

20.2.14.10. Market Revenue and Forecast, by Ingredients (2017-2030)

20.2.14.11. Market Revenue and Forecast, by Strength (2017-2030)

20.2.14.12. Market Revenue and Forecast, by End Use (2017-2030)

20.2.14.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)

20.2.15. Rest of Europe

20.2.15.1. Market Revenue and Forecast, by Type (2017-2030)

20.2.15.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

20.2.15.3. Market Revenue and Forecast, by Packaging (2017-2030)

20.2.15.4. Market Revenue and Forecast, by Container (2017-2030)

20.2.15.5. Market Revenue and Forecast, by Therapeutics (2017-2030)

20.2.15.6. Market Revenue and Forecast, by Availability (2017-2030)

20.2.15.7. Market Revenue and Forecast, by Treatment (2017-2030)

20.2.15.8. Market Revenue and Forecast, by Application (2017-2030)

20.2.15.9. Market Revenue and Forecast, by Source (2017-2030)

20.2.15.10. Market Revenue and Forecast, by Ingredients (2017-2030)

20.2.15.11. Market Revenue and Forecast, by Strength (2017-2030)

20.2.15.12. Market Revenue and Forecast, by End Use (2017-2030)

20.2.15.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)

20.3. APAC

20.3.1. Market Revenue and Forecast, by Type (2017-2030)

20.3.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

20.3.3. Market Revenue and Forecast, by Packaging (2017-2030)

20.3.4. Market Revenue and Forecast, by Container (2017-2030)

20.3.5. Market Revenue and Forecast, by Therapeutics (2017-2030)

20.3.6. Market Revenue and Forecast, by Availability (2017-2030)

20.3.7. Market Revenue and Forecast, by Treatment (2017-2030)

20.3.8. Market Revenue and Forecast, by Application (2017-2030)

20.3.9. Market Revenue and Forecast, by Source (2017-2030)

20.3.10. Market Revenue and Forecast, by Ingredients (2017-2030)

20.3.11. Market Revenue and Forecast, by Strength (2017-2030)

20.3.12. Market Revenue and Forecast, by End Use (2017-2030)

20.3.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)

20.3.12. India

20.3.12.1. Market Revenue and Forecast, by Type (2017-2030)

20.3.12.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

20.3.12.3. Market Revenue and Forecast, by Packaging (2017-2030)

20.3.12.4. Market Revenue and Forecast, by Container (2017-2030)

20.3.12.5. Market Revenue and Forecast, by Therapeutics (2017-2030)

20.3.12.6. Market Revenue and Forecast, by Availability (2017-2030)

20.3.12.7. Market Revenue and Forecast, by Treatment (2017-2030)

20.3.12.8. Market Revenue and Forecast, by Application (2017-2030)

20.3.12.9. Market Revenue and Forecast, by Source (2017-2030)

20.3.12.10. Market Revenue and Forecast, by Ingredients (2017-2030)

20.3.12.11. Market Revenue and Forecast, by Strength (2017-2030)

20.3.12.12. Market Revenue and Forecast, by End Use (2017-2030)

20.3.13.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)

20.3.13. China

20.3.13.1. Market Revenue and Forecast, by Type (2017-2030)

20.3.13.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

20.3.13.3. Market Revenue and Forecast, by Packaging (2017-2030)

20.3.13.4. Market Revenue and Forecast, by Container (2017-2030)

20.3.13.5. Market Revenue and Forecast, by Therapeutics (2017-2030)

20.3.13.6. Market Revenue and Forecast, by Availability (2017-2030)

20.3.13.7. Market Revenue and Forecast, by Treatment (2017-2030)

20.3.13.8. Market Revenue and Forecast, by Application (2017-2030)

20.3.13.9. Market Revenue and Forecast, by Source (2017-2030)

20.3.13.10. Market Revenue and Forecast, by Ingredients (2017-2030)

20.3.13.11. Market Revenue and Forecast, by Strength (2017-2030)

20.3.13.12. Market Revenue and Forecast, by End Use (2017-2030)

20.3.13.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)

20.3.14. Japan

20.3.14.1. Market Revenue and Forecast, by Type (2017-2030)

20.3.14.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

20.3.14.3. Market Revenue and Forecast, by Packaging (2017-2030)

20.3.14.4. Market Revenue and Forecast, by Container (2017-2030)

20.3.14.5. Market Revenue and Forecast, by Therapeutics (2017-2030)

20.3.14.6. Market Revenue and Forecast, by Availability (2017-2030)

20.3.14.7. Market Revenue and Forecast, by Treatment (2017-2030)

20.3.14.8. Market Revenue and Forecast, by Application (2017-2030)

20.3.14.9. Market Revenue and Forecast, by Source (2017-2030)

20.3.14.10. Market Revenue and Forecast, by Ingredients (2017-2030)

20.3.14.11. Market Revenue and Forecast, by Strength (2017-2030)

20.3.14.12. Market Revenue and Forecast, by End Use (2017-2030)

20.3.14.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)

20.3.15. Rest of APAC

20.3.15.1. Market Revenue and Forecast, by Type (2017-2030)

20.3.15.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

20.3.15.3. Market Revenue and Forecast, by Packaging (2017-2030)

20.3.15.4. Market Revenue and Forecast, by Container (2017-2030)

20.3.15.5. Market Revenue and Forecast, by Therapeutics (2017-2030)

20.3.15.6. Market Revenue and Forecast, by Availability (2017-2030)

20.3.15.7. Market Revenue and Forecast, by Treatment (2017-2030)

20.3.15.8. Market Revenue and Forecast, by Application (2017-2030)

20.3.15.9. Market Revenue and Forecast, by Source (2017-2030)

20.3.15.10. Market Revenue and Forecast, by Ingredients (2017-2030)

20.3.15.11. Market Revenue and Forecast, by Strength (2017-2030)

20.3.15.12. Market Revenue and Forecast, by End Use (2017-2030)

20.3.15.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)

20.4. MEA

20.4.1. Market Revenue and Forecast, by Type (2017-2030)

20.4.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

20.4.3. Market Revenue and Forecast, by Packaging (2017-2030)

20.4.4. Market Revenue and Forecast, by Container (2017-2030)

20.4.5. Market Revenue and Forecast, by Therapeutics (2017-2030)

20.4.6. Market Revenue and Forecast, by Availability (2017-2030)

20.4.7. Market Revenue and Forecast, by Treatment (2017-2030)

20.4.8. Market Revenue and Forecast, by Application (2017-2030)

20.4.9. Market Revenue and Forecast, by Source (2017-2030)

20.4.10. Market Revenue and Forecast, by Ingredients (2017-2030)

20.4.11. Market Revenue and Forecast, by Strength (2017-2030)

20.4.12. Market Revenue and Forecast, by End Use (2017-2030)

20.4.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)

20.4.12. GCC

20.4.12.1. Market Revenue and Forecast, by Type (2017-2030)

20.4.12.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

20.4.12.3. Market Revenue and Forecast, by Packaging (2017-2030)

20.4.12.4. Market Revenue and Forecast, by Container (2017-2030)

20.4.12.5. Market Revenue and Forecast, by Therapeutics (2017-2030)

20.4.12.6. Market Revenue and Forecast, by Availability (2017-2030)

20.4.12.7. Market Revenue and Forecast, by Treatment (2017-2030)

20.4.12.8. Market Revenue and Forecast, by Application (2017-2030)

20.4.12.9. Market Revenue and Forecast, by Source (2017-2030)

20.4.12.10. Market Revenue and Forecast, by Ingredients (2017-2030)

20.4.12.11. Market Revenue and Forecast, by Strength (2017-2030)

20.4.12.12. Market Revenue and Forecast, by End Use (2017-2030)

20.4.12.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)

20.4.13. North Africa

20.4.13.1. Market Revenue and Forecast, by Type (2017-2030)

20.4.13.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

20.4.13.3. Market Revenue and Forecast, by Packaging (2017-2030)

20.4.13.4. Market Revenue and Forecast, by Container (2017-2030)

20.4.13.5. Market Revenue and Forecast, by Therapeutics (2017-2030)

20.4.13.6. Market Revenue and Forecast, by Availability (2017-2030)

20.4.13.7. Market Revenue and Forecast, by Treatment (2017-2030)

20.4.13.8. Market Revenue and Forecast, by Application (2017-2030)

20.4.13.9. Market Revenue and Forecast, by Source (2017-2030)

20.4.13.10. Market Revenue and Forecast, by Ingredients (2017-2030)

20.4.13.11. Market Revenue and Forecast, by Strength (2017-2030)

20.4.13.12. Market Revenue and Forecast, by End Use (2017-2030)

20.4.13.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)

20.4.14. South Africa

20.4.14.1. Market Revenue and Forecast, by Type (2017-2030)

20.4.14.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

20.4.14.3. Market Revenue and Forecast, by Packaging (2017-2030)

20.4.14.4. Market Revenue and Forecast, by Container (2017-2030)

20.4.14.5. Market Revenue and Forecast, by Therapeutics (2017-2030)

20.4.14.6. Market Revenue and Forecast, by Availability (2017-2030)

20.4.14.7. Market Revenue and Forecast, by Treatment (2017-2030)

20.4.14.8. Market Revenue and Forecast, by Application (2017-2030)

20.4.14.9. Market Revenue and Forecast, by Source (2017-2030)

20.4.14.10. Market Revenue and Forecast, by Ingredients (2017-2030)

20.4.14.11. Market Revenue and Forecast, by Strength (2017-2030)

20.4.14.12. Market Revenue and Forecast, by End Use (2017-2030)

20.4.14.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)

20.4.15. Rest of MEA

20.4.15.1. Market Revenue and Forecast, by Type (2017-2030)

20.4.15.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

20.4.15.3. Market Revenue and Forecast, by Packaging (2017-2030)

20.4.15.4. Market Revenue and Forecast, by Container (2017-2030)

20.4.15.5. Market Revenue and Forecast, by Therapeutics (2017-2030)

20.4.15.6. Market Revenue and Forecast, by Availability (2017-2030)

20.4.15.7. Market Revenue and Forecast, by Treatment (2017-2030)

20.4.15.8. Market Revenue and Forecast, by Application (2017-2030)

20.4.15.9. Market Revenue and Forecast, by Source (2017-2030)

20.4.15.10. Market Revenue and Forecast, by Ingredients (2017-2030)

20.4.15.11. Market Revenue and Forecast, by Strength (2017-2030)

20.4.15.12. Market Revenue and Forecast, by End Use (2017-2030)

20.4.15.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)

20.5. Latin America

20.5.1. Market Revenue and Forecast, by Type (2017-2030)

20.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

20.5.3. Market Revenue and Forecast, by Packaging (2017-2030)

20.5.4. Market Revenue and Forecast, by Container (2017-2030)

20.5.5. Market Revenue and Forecast, by Therapeutics (2017-2030)

20.5.6. Market Revenue and Forecast, by Availability (2017-2030)

20.5.7. Market Revenue and Forecast, by Treatment (2017-2030)

20.5.8. Market Revenue and Forecast, by Application (2017-2030)

20.5.9. Market Revenue and Forecast, by Source (2017-2030)

20.5.10. Market Revenue and Forecast, by Ingredients (2017-2030)

20.5.11. Market Revenue and Forecast, by Strength (2017-2030)

20.5.12. Market Revenue and Forecast, by End Use (2017-2030)

20.5.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)

20.5.12. Brazil

20.5.12.1. Market Revenue and Forecast, by Type (2017-2030)

20.5.12.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

20.5.12.3. Market Revenue and Forecast, by Packaging (2017-2030)

20.5.12.4. Market Revenue and Forecast, by Container (2017-2030)

20.5.12.5. Market Revenue and Forecast, by Therapeutics (2017-2030)

20.5.12.6. Market Revenue and Forecast, by Availability (2017-2030)

20.5.12.7. Market Revenue and Forecast, by Treatment (2017-2030)

20.5.12.8. Market Revenue and Forecast, by Application (2017-2030)

20.5.12.9. Market Revenue and Forecast, by Source (2017-2030)

20.5.12.10. Market Revenue and Forecast, by Ingredients (2017-2030)

20.5.12.11. Market Revenue and Forecast, by Strength (2017-2030)

20.5.12.12. Market Revenue and Forecast, by End Use (2017-2030)

20.5.12.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)

20.5.13. Rest of LATAM

20.5.13.1. Market Revenue and Forecast, by Type (2017-2030)

20.5.13.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

20.5.13.3. Market Revenue and Forecast, by Packaging (2017-2030)

20.5.13.4. Market Revenue and Forecast, by Container (2017-2030)

20.5.13.5. Market Revenue and Forecast, by Therapeutics (2017-2030)

20.5.13.6. Market Revenue and Forecast, by Availability (2017-2030)

20.5.13.7. Market Revenue and Forecast, by Treatment (2017-2030)

20.5.13.8. Market Revenue and Forecast, by Application (2017-2030)

20.5.13.9. Market Revenue and Forecast, by Source (2017-2030)

20.5.13.10. Market Revenue and Forecast, by Ingredients (2017-2030)

20.5.13.11. Market Revenue and Forecast, by Strength (2017-2030)

20.5.13.12. Market Revenue and Forecast, by End Use (2017-2030)

20.5.13.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)

Chapter 21. Company Profiles

21.1. GlaxoSmithKline plc

21.1.1. Company Overview

21.1.2. Product Offerings

21.1.3. Financial Performance

21.1.4. Recent Initiatives

21.2. Pfizer, Inc.

21.2.1. Company Overview

21.2.2. Product Offerings

21.2.3. Financial Performance

21.2.4. Recent Initiatives

21.3. Baxter

21.3.1. Company Overview

21.3.2. Product Offerings

21.3.3. Financial Performance

21.3.4. Recent Initiatives

21.4. Leo Pharma A/S

21.4.1. Company Overview

21.4.2. Product Offerings

21.4.3. Financial Performance

21.4.4. Recent Initiatives

21.5. Sanofi

21.5.1. Company Overview

21.5.2. Product Offerings

21.5.3. Financial Performance

21.5.4. Recent Initiatives

21.6. Dr. Reddy’s Laboratories Ltd.

21.6.1. Company Overview

21.6.2. Product Offerings

21.6.3. Financial Performance

21.6.4. Recent Initiatives

21.7. Aspen Holdings

21.7.1. Company Overview

21.7.2. Product Offerings

21.7.3. Financial Performance

21.7.4. Recent Initiatives

21.8. B. Braun Medical Inc.

21.8.1. Company Overview

21.8.2. Product Offerings

21.8.3. Financial Performance

21.8.4. Recent Initiatives

21.9. Fresenius SE & Co. KGaA

21.9.1. Company Overview

21.9.2. Product Offerings

21.9.3. Financial Performance

21.9.4. Recent Initiatives

21.10. Teva Pharmaceutical Industries Ltd.

21.10.1. Company Overview

21.10.2. Product Offerings

21.10.3. Financial Performance

21.10.4. Recent Initiatives

Chapter 22. Research Methodology

22.1. Primary Research

22.2. Secondary Research

22.3. Assumptions

Chapter 23. Appendix

23.1. About Us

23.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com

 

Tags:

Post a Comment

0 Comments